Immune-Desert Tumor Microenvironment in Thoracic SMARCA4-Deficient Undifferentiated Tumors with Limited Efficacy of Immune Checkpoint Inhibitors.

Date publication

mars 2022

Journal

The oncologist

Auteurs

Membres identifiés du Cancéropôle Est :
Pr CHENARD Marie-Pierre , Dr DAVIDSON Irwin , Pr KURTZ Jean-Emmanuel , Dr LINDNER Véronique , Pr MALOUF Gabriel , Pr MASCAUX Céline , Dr GANTZER Justine

Tous les auteurs :
Gantzer J, Davidson G, Vokshi B, Weingertner N, Bougoüin A, Moreira M, Lindner V, Lacroix G, Mascaux C, Chenard MP, Bertucci F, Davidson I, Kurtz JE, Sautès-Fridman C, Fridman WH, Malouf GG

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/35278076

Résumé

Thoracic SMARCA4-deficient undifferentiated tumors (SMARCA4-UT) are aggressive neoplasms. Data linking BAF alterations with tumor microenvironment (TME) and efficacy of immune checkpoint inhibitors (ICI) are contradictory. The TME of SMARCA4-UT and their response to ICI are unknown.

Mots clés

SMARCA4-deficiency, immune infiltrate, immunotherapy, sarcomas, thoracic tumors, tumor microenvironment

Référence

Oncologist. 2022 Mar 12;: